KYTX
Kyverna Therapeutics, Inc.
Latest Form 4:Purchase$1000KbyWestlake BioPartners Opportunity Fund I, L.P. (10% Owner) · filed Dec 22, 2025
Kyverna Therapeutics, Inc. (KYTX) has 12 SEC Form 4 filings (13 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: May 29, 2026.
Insiders have net bought $1000K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Warner Biddle
- Employees:130
- HQ:Emeryville, CA, US
- IPO:2024-02-09
Insider Buying
$1000K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
Market Cap
$491.2M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Westlake BioPartners Opportunity Fund I, L.P.First filing | 10% Owner | Purchase | 133,333 | $1000K | Dec 22 | SEC ↗ |
Related companies
Kyverna Therapeutics, Inc. is in the Healthcare sector.